問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Linkou Chang Gung Medical Foundation (在職)

Division of Neurology

更新時間：2023-09-19

吳秀娟Wu, Hsiu-Chuan
  • Principal Investigator
  • Clinical Trial Experience (year) 17 years 10 個月

  • serenawu@cgmh.org.tw

Recruiting Trial

21Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

吳秀娟

List

25Cases

2017-08-01 - 2025-07-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

2019-08-01 - 2021-07-31

Phase II

Alzheimer's Disease: Clinical Investigation and Neuroimage Studies Including 18F-PM-PBB3 and 18F-florbetapir (AV-45) PET Examination

  • Condition/Disease

    investigate the deposition patterns of tau protein with 18F-PM-PBB3 and amyloid protein with 18F-flobetapir in patients with amnestic mild cognitive impairment due to AD

  • Test Drug

    18F-AV-45 for Injection, and 18F-PM-PBB3 for Injection

Participate Sites
1Sites

Recruiting1Sites

2018-11-01 - 2023-10-31

Phase III

Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema following Large Hemispheric Infarction

  • Condition/Disease

    Brain Edema, Acute Stroke

  • Test Drug

    BIIB093

Participate Sites
4Sites

Recruiting4Sites

2023-05-01 - 2027-06-24

Phase III

A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, for Stroke Prevention After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack

  • Condition/Disease

    Ischemic Stroke; Ischemic Attack, Transient

  • Test Drug

    Milvexian

Participate Sites
13Sites

Recruiting13Sites

2019-07-01 - 2023-04-25

Phase III

A PHASE 3, RANDOMIZED, RATER-BLINDED, MULTI-CENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ALXN1840 ADMINISTERED FOR 48 WEEKS VERSUS STANDARD OF CARE IN PATIENTS WITH WILSON DISEASE AGED 12 YEARS AND OLDER WITH AN EXTENSION PERIOD OF UP TO 60 MONTHS

  • Condition/Disease

    WILSON DISEASE

  • Test Drug

    ALXN1840

Participate Sites
1Sites

Recruiting1Sites

1 2 3
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB